The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determining the abundance of dendritic cells (DCs) in a tumor tissue sample. The abundance of DCs characterized by enhanced expressions of XCR1, IRF8, BATF3 and FLT3 predicts clinical response to the PD-L1 blockade 5 treatment.

The present invention relates to a biosensor technique in which multiple types of target substances (biomarkers) contained in saliva or the like are allowed to be simultaneously measured or N samples for one target substance (biomarker) are allowed to be simultaneously measured and reliability of sensed results and high sensitivity are secured. A fluidic channel-based planar biosensor chip, in which a plurality of fluidic channels capable of measuring target substances (biomarkers) are embedded in one flat plate sensor chip and the flat plate sensor chip is measured by a light-emitting element (optical source) and a light-receiving element, and a biomarker measuring apparatus using the same are provided.

The present invention relates to a biosensor technique in which multiple types of target substances (biomarkers) contained in saliva or the like are allowed to be simultaneously measured or N samples for one target substance (biomarker) are allowed to be simultaneously measured and reliability of sensed results and high sensitivity are secured. A fluidic channel-based planar biosensor chip, in which a plurality of fluidic channels capable of measuring target substances (biomarkers) are embedded in one flat plate sensor chip and the flat plate sensor chip is measured by a light-emitting element (optical source) and a light-receiving element, and a biomarker measuring apparatus using the same are provided.

New antibodies and methods of use are described.

New antibodies and methods of use are described.

The present disclosure provides antibodies that specifically bind to botulinum neurotoxins. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment.

The present disclosure provides antibodies that specifically bind to botulinum neurotoxins. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment.

The present invention relates to human IgG Fc domain variants with improved effector function and uses thereof.

The present invention relates to human IgG Fc domain variants with improved effector function and uses thereof.

The disclosure generally relates to the detection of symmetrical dimethylarginine (SDMA). More particularly, the disclosure relates to the detection of SDMA using a solid phase. The disclosure provides devices, reagents, kits and methods for detecting symmetrical dimethyl arginine (SDMA) in sample, such as a biological sample from an animal. The method includes detecting the presence or amount of SDMA in the sample by using an immunoassay format, such as a competitive immunoassay. The assay includes the use of antibodies to SDMA that are specific for SDMA and that have less affinity for other arginine derivatives.